Virginia localities sue pharmaceutical giants over insulin costs – msn/WaPost
“About 11 percent of the U.S. population has diabetes. Eli Lilly, Novo Nordisk and Sanofi Aventis control 90 percent of the world’s insulin supply, while CVS Caremark, Express Scripts and OptumRx manage about 80 percent of the U.S. insulin market. The Virginia lawsuits characterize the six companies as an ‘oligopoly,’ or a market controlled by a small number of participants, the same term used by California Attorney General Rob Bonta (D) in a similar lawsuit filed in January in that state’s courts.”
$13.5 Million Eli Lilly Settlement Includes Four-Year Cap on Insulin Prices – classaction.org
“A RAND Corporation study from 2019 found insulin in the United States is substantially more expensive than prices in 33 other countries. The average price across all insulins in the U.S. was $98.70, compared to $6.94 in Australia, $12.00 in Canada, and $7.52 in the UK.”